Published in Prog Neurobiol on July 01, 1999
Cannabis use and mental health in young people: cohort study. BMJ (2002) 3.26
Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A (2002) 2.95
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry (2012) 2.87
Distinct timing in the activity of cannabinoid-sensitive and cannabinoid-insensitive basket cells. Nat Neurosci (2006) 2.59
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A (2009) 1.75
A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A (2002) 1.74
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry (2008) 1.59
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology (2011) 1.57
Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol (2002) 1.53
Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol (2007) 1.47
Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol (2002) 1.40
Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol (2004) 1.35
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J (2001) 1.29
Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) (2003) 1.24
Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol (2001) 1.22
Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res (2009) 1.22
Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl) (2010) 1.22
Endocannabinoids and exercise. Br J Sports Med (2004) 1.19
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.17
Neuroimaging of children following prenatal drug exposure. Semin Cell Dev Biol (2009) 1.17
Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. J Psychiatr Res (2008) 1.14
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav (2007) 1.13
Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res (2013) 1.10
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res (2006) 1.08
Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry (2013) 1.08
New insights on neurobiological mechanisms underlying alcohol addiction. Neuropharmacology (2012) 1.07
Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res (2007) 1.07
Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune Pharmacol (2011) 1.04
Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl) (2007) 1.04
Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) (2012) 1.02
Endocannabinoids and their implications for epilepsy. Epilepsy Curr (2005) 1.00
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) (2008) 1.00
Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology (2010) 0.97
CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) (2004) 0.96
Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol (2004) 0.96
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem (2012) 0.96
Endocannabinoid modulation of fear responses: learning and state-dependent performance effects. J Psychopharmacol (2008) 0.95
Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice. Br J Pharmacol (2001) 0.94
Harm reduction--the cannabis paradox. Harm Reduct J (2005) 0.94
Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology (Berl) (2004) 0.94
Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl) (2010) 0.93
Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future. Front Psychiatry (2014) 0.93
Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol (2008) 0.93
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol (2007) 0.90
2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem (2009) 0.88
Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl) (2011) 0.88
Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl) (2008) 0.88
The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol (2011) 0.88
Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs. Front Behav Neurosci (2011) 0.88
Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment. CNS Drugs (2013) 0.87
Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. J Physiol (2003) 0.87
Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.87
Cannabinoids inhibit network-driven synapse loss between hippocampal neurons in culture. J Pharmacol Exp Ther (2008) 0.87
Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.87
THC Prevents MDMA Neurotoxicity in Mice. PLoS One (2010) 0.86
Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berl) (2004) 0.86
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat. Neurotoxicol Teratol (2010) 0.86
Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci (2007) 0.85
Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana. Behav Brain Res (2013) 0.85
Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology (Berl) (2008) 0.85
A novel non-CB1/TRPV1 endocannabinoid-mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons. Hippocampus (2010) 0.85
Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br J Pharmacol (2004) 0.84
Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.84
Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance. Front Behav Neurosci (2012) 0.83
A potential function of endocannabinoids in the selection of a navigation strategy by rats. Psychopharmacology (Berl) (2007) 0.83
The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl) (2004) 0.82
Brain levels of prostaglandins, endocannabinoids, and related lipids are affected by mating strategies. Int J Endocrinol (2013) 0.82
Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine. Br J Pharmacol (2014) 0.82
Mastering tricyclic ring systems for desirable functional cannabinoid activity. Eur J Med Chem (2013) 0.82
Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. Drug Alcohol Depend (2013) 0.81
Modulation of T-type calcium channels by bioactive lipids. Pflugers Arch (2014) 0.81
Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl) (2014) 0.81
Tetrahydrocannabinol induces brain mitochondrial respiratory chain dysfunction and increases oxidative stress: a potential mechanism involved in cannabis-related stroke. Biomed Res Int (2015) 0.81
Structural network topology revealed by white matter tractography in cannabis users: a graph theoretical analysis. Brain Connect (2012) 0.80
Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice. Psychopharmacology (Berl) (2009) 0.80
Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int Immunopharmacol (2010) 0.80
Purines released from astrocytes inhibit excitatory synaptic transmission in the ventral horn of the spinal cord. Front Neural Circuits (2014) 0.80
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin Neurosci Res (2005) 0.80
Epigenetics, drugs of abuse, and the retroviral promoter. J Neuroimmune Pharmacol (2013) 0.80
Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Sci Int (2014) 0.80
MDMA attenuates THC withdrawal syndrome in mice. Psychopharmacology (Berl) (2007) 0.80
Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction. Anat Cell Biol (2011) 0.79
Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. J Biol Chem (2016) 0.79
The CB1 receptor as an important mediator of hedonic reward processing. Neuropsychopharmacology (2014) 0.78
Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis. Addict Biol (2011) 0.78
Septo-hippocampo-septal loop and memory formation. Basic Clin Neurosci (2013) 0.78
Episodic memories and their relevance for psychoactive drug use and addiction. Front Behav Neurosci (2013) 0.78
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Front Psychiatry (2012) 0.78
Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin. J Neuroimmune Pharmacol (2016) 0.78
Rapid analysis of synthetic cannabinoids using a miniature mass spectrometer with ambient ionization capability. Talanta (2015) 0.78
Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.78
Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands. Bioorg Med Chem Lett (2011) 0.78
Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol (2003) 0.77
Endocannabinoid-dependent modulation of phasic dopamine signaling encodes external and internal reward-predictive cues. Front Psychiatry (2014) 0.77
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. J Pharm Bioallied Sci (2011) 0.77
Assessing topographical orientation skills in cannabis users. ScientificWorldJournal (2012) 0.76
Inhibition of stimulus-triggered and spontaneous epileptiform activity in rat hippocampal slices by the Aconitum alkaloid mesaconitine. Eur J Pharmacol (1998) 0.86
Calcium-dependent, sustained enhancement of excitability during washout of aconitine in rat hippocampal slices. Exp Brain Res (1997) 0.80
Structure-dependent inhibitory action of the Aconitum alkaloids 14-benzoyltalitasamine and talitasamine in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.79
Electrophysiological effects of aconitine in rat hippocampal slices. Neuropharmacology (1996) 0.78
Aconitine inhibits epileptiform activity in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.77
Structure-dependent differences in the effects of the Aconitum alkaloids lappaconitine, N-desacetyllappaconitine and lappaconidine in rat hippocampal slices. Brain Res (1997) 0.77
Effects of the Aconitum alkaloid songorine on synaptic transmission and paired-pulse facilitation of CA1 pyramidal cells in rat hippocampal slices. Br J Pharmacol (1998) 0.76
Inhibition of neuronal activity in rat hippocampal slices by Aconitum alkaloids. Brain Res (1996) 0.76
Bicuculline-induced epileptiform activity in rat hippocampal slices: suppression by Aconitum alkaloids. Planta Med (1997) 0.76
Frequency-dependent inhibition of neuronal activity by lappaconitine in normal and epileptic hippocampal slices. Br J Pharmacol (1996) 0.75
Inhibition of rat hippocampal excitability by the plant alkaloid 3-acetylaconitine mediated by interaction with voltage-dependent sodium channels. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.75
Electrophysiological actions of the plant alkaloid 6-benzoylheteratisine in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.75
Age-dependent differences in sensitivity to aconitine of rat hippocampal slices. Neurosci Lett (1996) 0.75
Effects of the Aconitum alkaloid mesaconitine in rat hippocampal slices and the involvement of alpha- and beta-adrenoceptors. Br J Pharmacol (1998) 0.75
Effects of the alkaloids 6-benzoylheteratisine and heteratisine on neuronal activity in rat hippocampal slices. Neuropharmacology (1997) 0.75
Inhibition of rat hippocampal excitability by the Aconitum alkaloid, 1-benzoylnapelline, but not by napelline. Eur J Pharmacol (1997) 0.75
Effects of mesaconitine on [3H]noradrenaline uptake and neuronal excitability in rat hippocampus. Exp Brain Res (1998) 0.75